GVK Biosciences (GVK BIO), an India-based, full-service Contract Research Organization (CRO) has teamed up with ResearchPoint Global (RPG). The company will now provide RPG access to an extensive network of experienced and proven investigative sites and country-specific regulatory, clinical and technical expertise.

RPG’s expansion into India offers numerous advantages for running clinical trials: a large population, qualified medical personnel, and well-established regulations. GVK BIO complements RPG’s current presence in the Americas, Europe (Western, Central, and Eastern) and Africa.

As the growth of India’s participation in global clinical programmes continues to increase at a rapid pace, RPG strategically sought to expand its reach to this region. According to The Goldman Sachs Group, Inc., “India presents an attractive region for clinical trials given a population of over one billion, a large number of English-speaking patients, and a well developed information technology industry.”

“We are strategically expanding our global footprint with qualified, CROs that have extensive drug development experience across a broad range of therapeutic areas,” said Matt Walker, executive vice president of Marketing and Business Development with ResearchPoint, a member of RPG.

“GVK Biosciences has built an exceptional reputation as a full-service clinical service provider in India and we look forward to leveraging their deep local knowledge for the benefit of our clients,” he added.

According to Paul Braconnier, Governing Board Member, RPG, GVK Biosciences expands upon the ResearchPoint Global objective to provide sponsors with the ability to conduct international studies.

Manni Kantipudi, president, GVK BIO stated that the partnership would enable the company to participate in global trials while focusing on local investigators/recruitment and leveraging lower local costs. While both ResearchPoint Global and GVK BIO are full service CROs offering services independently, together, we hope to offer faster patient recruitment and access to our complete suite of functional services including Clinical Data Management, Medical Writing, and Biostatistics.

“With our experience in several therapeutic areas, extensive investigator network, local regulatory expertise, and medical affairs capabilities, we are confident in bringing value to RPG. Our existing clients will benefit from our ability to recruit patients across multiple geographies through RPG,” said Dr Shoibal Mukherjee, senior vice president & head of Clinical Development, GVK BIO.